Omalizumab
Experts debate use of dual biologics to treat severe asthma
WASHINGTON — A debate at the American Thoracic Society International Conference changed some minds about whether providers could or should combine and overlap biologic treatments to treat severe asthma.
Tezepelumab improves asthma outcomes regardless of prior omalizumab use
WASHINGTON — Tezepelumab reduced annualized asthma exacerbation rates compared with placebo among patients with severe, uncontrolled asthma regardless of prior omalizumab use, according to study results.
Dupilumab outperforms other biologics in asthma outcomes
Patients with asthma and specific eosinophil and IgE levels experienced greater improvements in exacerbations and FEV1 with dupilumab compared with other biologics, according to a study.
Omalizumab eases extra-respiratory symptoms in aspirin-exacerbated respiratory disease
The extra-respiratory symptoms of aspirin-exacerbated respiratory disease improved with omalizumab at baseline and during aspirin challenges, according to a study published in The Journal of Allergy & Clinical Immunology.
COVID-19 less prevalent among patients with asthma taking biologics
SAN ANTONIO — Patients taking biologics for severe asthma experienced COVID-19 than those who were not taking biologics, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Biologics reduce exacerbations among patients with asthma, allergic rhinitis
SAN ANTONIO — Patients with severe asthma and allergic rhinitis experienced fewer exacerbations after taking a biologic for 6 months, with greater decreases seen for biologics other than omalizumab, according to the CHRONICLE study.
Peanut oral immunotherapy plus omalizumab positively impacts adolescents’ quality of life
Adolescents with severe peanut allergy experienced clinically relevant improvements in health-related quality of life with oral immunotherapy and omalizumab, according to a letter published in Clinical and Translational Allergy.
Omalizumab boosts time to clinically meaningful response in chronic spontaneous urticaria
LOUISVILLE, Ky. — Patients assigned omalizumab for moderate to severe chronic spontaneous urticaria experienced superior time to clinically meaningful response compared with those on placebo, according to study results.
VIDEO: Choice of biologic ‘not an easy task’ in severe asthma
In this Healio video exclusive, Nicola A. Hanania, MD, MS, discusses a CHEST Annual Meeting symposium in which he participated that addressed choice of biologic in severe asthma.
Experts debate the role of biologics in asthma treatment
NASHVILLE, Tenn. — Experts found both consensus and contention during a roundtable discussion of the use of biologics to treat severe asthma, modelled on the ESPN program “Pardon the Interruption,” during the CHEST Annual Meeting.